A Phase 3 interventional study of NVA237 and Long-acting beta 2-agonist (LABA) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-03-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 20th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 26th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 36th largest by enrollment of the 116 interventional ones that give a count, is one of 22 that started in 2012, is one of 59 in phase 3, and was the 74th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVA237 dose 1
Drug: NVA237
QAB149
Drug: Long-acting beta 2-agonist (LABA) · Drug: Placebo
NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
Placebo to match QAB149
Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.
Time frame: 52 weeks
Time to Treatment Discontinuation
Discontinuation rates are calculated using the Kaplan Meier method. The protocol allowed patients to discontinue outside the treatment window, hence we have a patient who discontinued at Day 388. Reasons for discontinuing treatment are Subject/guardian decision, Adverse event, Protocol deviation Lack of efficacy, Physician decision, Dosing error, Disease improvement under study, Pregnancy, Technical problems
Time frame: 52 Weeks
Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52
Change from baseline in pre-dose trough FEV1 was analyzed using a repeated measures analysis of covariance model which contained treatment, baseline FEV1, visit, baseline smoking status, baseline ICS use, COPD severity and treatment by visit, visit by baseline FEV1 interactions. An unstructured variance-covariance error matrix was used .Pulmonary function assessments were performed using centralized spirometry according to international standards. Pre-dose trough FEV1 was defined as the mean of FEV1 at -45 min and -15 min before the morning dose at Week 52. Baseline FEV1 was defined as the mean of the pre-dose FEV1 at -45 min and -15 min on Day 1.
Time frame: -45 min and -15 minutes baseline and at Week 52
Change From Baseline in Pre-dose Forced Expiratory Volume (FEV1) in One Second at All Post Baseline Timepoints
Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.
Time frame: -45 min and -15 minutes baseline and at Week 52
Change From Baseline in Pre-dose Forced Vital Capacity (FVC) at All Post-baseline Timepoints
Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FVC was defined as the average of the pre-dose FVC measured at -45 minutes (min) and -15 min at day 1.
Time frame: -45 min and -15 minutes baseline and at Week 52
Change From Baseline in COPD Symptoms
The total symptom score was defined as the sum of individual cores for respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and reathlessness. Where a patient had a morning score and an evening score for an individual symptom on one particular day then the worst score was to be taken as the daily score for that symptom. Each symptom scale ranged from 0-3 where 0 was no symptoms and 3 was the worst. The total daily/daytime/nighttime symptom score consists of looking at the score for 6 symptoms and can therefore have a minimum score of 0 or a maximum of 18.
Time frame: 52 weeks
Change From Baseline in COPD Symptoms
Percentage of days with 'no daytime symptoms' A day with 'no daytime symptoms' was defined from the diary data as any day where the patient had recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) and no puffs of rescue medication during the past 12 hours (approximately 8 am to 8pm). However, a patient was not considered symptom free if they had used rescue medication that day even if his/her total daytime symptoms score was zero. Percentage of nights with 'no nighttime awakenings' A night with 'no nighttime awakenings' was defined from diary data as any night where the patient did not wake up due to symptoms. The total number of nights with 'no nighttime awakenings' over the treatment period was divided by the total number of nights where diary recordings had been made in order to derive the percentage nights with 'no nighttime awakenings'.
Time frame: 52 weeks
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
The number of puffs of rescue medication taken in the previous 12 hours was recorded by the patients in the eDiary in the morning and evening. The total number of puffs of rescue medication per day over the 52 week treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator. Change from baseline in number of puffs were analyzed using a linear mixed model which contained treatment, baseline number of puffs, baseline smoking status, baseline ICS use and COPD disease severity as fixed effects with center as a random effect
Time frame: 52 weeks
Time to First COPD Exacerbation (Moderate or Severe).
COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if hospitalizations were required. Rates are calculated using the Kaplan Meier method.
Time frame: 52 weeks
| Milestone | NVA237 | QAB149 |
|---|---|---|
| Started | 254 | 257 |
| Safety set | 251 | 256 |
| Full analysis set (fas) | 251 | 255 |
| Completed | 207 | 210 |
| Not completed | 47 | 47 |
| Withdrew: Study terminated by sponsor | 0 | 3 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 4 | 2 |
| Withdrew: Lost to follow-up | 10 | 7 |
| Withdrew: Subject/guardian decision | 31 | 35 |
Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.
| Percentage of participants | NVA237 | QAB149 |
|---|---|---|
| Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate | 77.3 | 77 |
Discontinuation rates are calculated using the Kaplan Meier method. The protocol allowed patients to discontinue outside the treatment window, hence we have a patient who discontinued at Day 388. Reasons for discontinuing treatment are Subject/guardian decision, Adverse event, Protocol deviation Lack of efficacy, Physician decision, Dosing error, Disease improvement under study, Pregnancy, Technical problems
| Days | NVA237 | QAB149 |
|---|---|---|
| Time to Treatment Discontinuation | NA (NA to NA) | 388 (388 to NA) |
Change from baseline in pre-dose trough FEV1 was analyzed using a repeated measures analysis of covariance model which contained treatment, baseline FEV1, visit, baseline smoking status, baseline ICS use, COPD severity and treatment by visit, visit by baseline FEV1 interactions. An unstructured variance-covariance error matrix was used .Pulmonary function assessments were performed using centralized spirometry according to international standards. Pre-dose trough FEV1 was defined as the mean of FEV1 at -45 min and -15 min before the morning dose at Week 52. Baseline FEV1 was defined as the mean of the pre-dose FEV1 at -45 min and -15 min on Day 1.
| Liters | NVA237 | QAB149 |
|---|---|---|
| Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52 | 0.056 ± 0.0211 | 0.060 ± 0.0213 |
Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.
| Liters | NVA237 | QAB149 |
|---|---|---|
| Day 29/-45min | 0.104 ± 0.1848 | 0.118 ± 0.2093 |
| Day 29/-15min | 0.123 ± 0.1872 | 0.138 ± 0.2061 |
| Day 57/-45min | 0.098 ± 0.2017 | 0.101 ± 0.2091 |
| Day 57/-15min | 0.120 ± 0.2025 | 0.107 ± 0.2111 |
| Day 85/-45min | 0.105 ± 0.2410 | 0.085 ± 0.2255 |
| Day 85/-15min | 0.111 ± 0.2137 | 0.099 ± 0.2328 |
| Day 141/-45min | 0.071 ± 0.2168 | 0.089 ± 0.2595 |
| Day 141/-15min | 0.096 ± 0.2060 | 0.108 ± 0.2670 |
| Day 197/-45min | 0.071 ± 0.2370 | 0.082 ± 0.2637 |
| Day 197/-15min | 0.073 ± 0.2150 | 0.090 ± 0.2827 |
| Day 253/-45min | 0.092 ± 0.2774 | 0.087 ± 0.2679 |
| Day 253/-15min | 0.094 ± 0.2100 | 0.103 ± 0.2659 |
| Day 309/-45min | 0.068 ± 0.2850 | 0.094 ± 0.2594 |
| Day 309/-15min | 0.088 ± 0.2845 | 0.112 ± 0.2638 |
| Day 365/-45min | 0.057 ± 0.2541 | 0.088 ± 0.2521 |
| Day 365/-15min | 0.087 ± 0.2592 | 0.090 ± 0.2627 |
Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FVC was defined as the average of the pre-dose FVC measured at -45 minutes (min) and -15 min at day 1.
| Liters | NVA237 | QAB149 |
|---|---|---|
| Day 29/-45min | 0.191 ± 0.3433 | 0.170 ± 0.3536 |
| Day 29/-15min | 0.217 ± 0.3440 | 0.194 ± 0.3495 |
| Day 57/-45min | 0.168 ± 0.3501 | 0.140 ± 0.3655 |
| Day 57/-15min | 0.210 ± 0.3414 | 0.178 ± 0.3610 |
| Day 85/-45min | 0.171 ± 0.3907 | 0.094 ± 0.3711 |
| Day 85/-15min | 0.188 ± 0.3875 | 0.118 ± 0.3823 |
| Day 141/-45min | 0.159 ± 0.3742 | 0.112 ± 0.3822 |
| Day 141/-15min | 0.182 ± 0.3706 | 0.141 ± 0.4068 |
| Day 197/-45min | 0.140 ± 0.3879 | 0.075 ± 0.4043 |
| Day 197/-15min | 0.133 ± 0.3992 | 0.083 ± 0.4183 |
| Day 253/-45min | 0.167 ± 0.4567 | 0.100 ± 0.4219 |
| Day 253/-15min | 0.153 ± 0.3703 | 0.125 ± 0.3984 |
| Day 309/-45min | 0.120 ± 0.4539 | 0.094 ± 0.4122 |
| Day 309/-15min | 0.149 ± 0.4451 | 0.114 ± 0.4207 |
| Day 365/-45min | 0.116 ± 0.4053 | 0.109 ± 0.4426 |
| Day 365/-15min | 0.143 ± 0.3970 | 0.097 ± 0.4171 |
The total symptom score was defined as the sum of individual cores for respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and reathlessness. Where a patient had a morning score and an evening score for an individual symptom on one particular day then the worst score was to be taken as the daily score for that symptom. Each symptom scale ranged from 0-3 where 0 was no symptoms and 3 was the worst. The total daily/daytime/nighttime symptom score consists of looking at the score for 6 symptoms and can therefore have a minimum score of 0 or a maximum of 18.
| scores on a scale | NVA237 | QAB149 |
|---|---|---|
| Daily total symptom score (n=231, 227) | -1.18 ± 0.137 | -1.47 ± 0.137 |
| Daytime total symptom score (n=221, 220) | -0.95 ± 0.129 | -1.14 ± 0.129 |
| Nighttime total symptom score (n=226, 222) | -1.11 ± 0.126 | -1.25 ± 0.128 |
Percentage of days with 'no daytime symptoms' A day with 'no daytime symptoms' was defined from the diary data as any day where the patient had recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) and no puffs of rescue medication during the past 12 hours (approximately 8 am to 8pm). However, a patient was not considered symptom free if they had used rescue medication that day even if his/her total daytime symptoms score was zero. Percentage of nights with 'no nighttime awakenings' A night with 'no nighttime awakenings' was defined from diary data as any night where the patient did not wake up due to symptoms. The total number of nights with 'no nighttime awakenings' over the treatment period was divided by the total number of nights where diary recordings had been made in order to derive the percentage nights with 'no nighttime awakenings'.
| Percentage of days / nights | NVA237 | QAB149 |
|---|---|---|
| Nights with no nighttime awakenings (n=226, 222) | 17.4 ± 1.84 | 18.0 ± 1.86 |
| Days with no daytime symptoms (n=221, 220) | 6.0 ± 1.38 | 5.1 ± 1.38 |
| Days able to perform daily activities(n=221,220) | 5.4 ± 2.09 | 8.5 ± 2.10 |
The number of puffs of rescue medication taken in the previous 12 hours was recorded by the patients in the eDiary in the morning and evening. The total number of puffs of rescue medication per day over the 52 week treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator. Change from baseline in number of puffs were analyzed using a linear mixed model which contained treatment, baseline number of puffs, baseline smoking status, baseline ICS use and COPD disease severity as fixed effects with center as a random effect
| Number of puffs | NVA237 | QAB149 |
|---|---|---|
| Daily (n=231, 227) | -1.16 ± 0.199 | -1.79 ± 0.199 |
| Daytime (n=221, 220) | -0.71 ± 0.112 | -1.05 ± 0.112 |
| Nighttime (n=226, 222) | -0.52 ± 0.094 | -0.73 ± 0.095 |
COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if hospitalizations were required. Rates are calculated using the Kaplan Meier method.
| Days | NVA237 | QAB149 |
|---|---|---|
| Time to First COPD Exacerbation (Moderate or Severe). | NA (NA to NA) | NA (NA to NA) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NVA237 | — | 33/251 (13.1%) | 165/251 (65.7%) |
| QAB149 | — | 34/256 (13.3%) | 170/256 (66.4%) |
| Event | NVA237 | QAB149 |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 11/251 | 12/256 |
| PNEUMONIAInfections and infestations | 5/251 | 4/256 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 3/251 | 0/256 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/251 | 1/256 |
| NON-CARDIAC CHEST PAINGeneral disorders | 2/251 | 0/256 |
| ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 2/251 | 2/256 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/251 | 2/256 |
| CARDIAC ARRESTCardiac disorders | 0/251 | 2/256 |
| SEPSISInfections and infestations | 0/251 | 2/256 |
| HYPONATRAEMIAMetabolism and nutrition disorders | 0/251 | 2/256 |
| Event | NVA237 | QAB149 |
|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 83/251 | 88/256 |
| NASOPHARYNGITISInfections and infestations | 20/251 | 27/256 |
| COUGHRespiratory, thoracic and mediastinal disorders | 18/251 | 20/256 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 14/251 | 16/256 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 13/251 | 9/256 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 12/251 | 12/256 |
| SINUSITISInfections and infestations | 10/251 | 12/256 |
| FATIGUEGeneral disorders | 11/251 | 3/256 |
| BRONCHITISInfections and infestations | 11/251 | 9/256 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 11/251 | 11/256 |
The Safety set included all patients that received at least one dose of study drug and had at least one-post baseline assessment . Subjects were analyzed according to the treatment they received (if a subject incorrectly took more than one treatment, the subject was analyzed according to the treatment they were randomized to).
| Age, Continuous(Years) | NVA237 | QAB149 | Total |
|---|---|---|---|
| Mean | 63.3 ± 9.15 | 63.2 ± 8.91 | 63.3 ± 9.02 |
| Sex: Female, Male(Participants) | NVA237 | QAB149 | Total |
|---|---|---|---|
| Female | 110 | 107 | 217 |
| Male | 141 | 149 | 290 |
The record gives a start of Oct 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →